RankAlpha logo
Back to Rankings

PROF

Profound MedicalC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
The bullish case is that 2025 showed real top-line traction: revenue rose 51% to $16.1M, recurring non-capital revenue rose to $9.73M, and management is explicitly investing behind direct sales and utilization growth for TULSA-PRO [#10-K-2026-03-05]. If quarterly updates confirm continued system placements and procedure growth, the current micro-cap valuation can rerate quickly.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +19.4.
What can break
Commercial adoption of TULSA-PRO may remain slower than the cost ramp behind the direct sales build-out.
Momentum
70
Value
36
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.25 · Bull $9.50 · Bear $4.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.35
Why
Momentum70 · Δ7d +19.4
Value36 · Δ7d -0.0
Sentiment49 · Δ7d +31.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
70
34% active weight
Current posture
7d trendImproving
Δ7d
+19.4
Δ21d
+58.2
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
49
33% active weight
Current posture
7d trendImproving
Δ7d
+31.1
Δ21d
+9.3
Why this grade

Composite grade C. Momentum 70.5 / Value 36.4 / Sentiment 49.5

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$245.54M
Beta
0.29
Shares Out
35.37M
P/E (TTM) · Derived
-4.3
P/S (TTM)
19.14
P/FCF (TTM) · Derived
-5.36
Rev YoY
+86.8%
EPS YoY
+30.6%
Gross Margin
+72.5%
Op Margin
-295.4%
Net Debt
-$49.79M
Current Ratio
4.18
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology